Deep Bio
Deep Bio is a Seoul-based medical AI company developing deep learning software for digital pathology, primarily for prostate and breast cancer detection and grading on whole-slide images, sold to hospitals and pathology labs via licensing and integration with major digital pathology platforms including Roche and PathAI.
- Company typePrivate
- Founded2015
- HeadquartersSeoul, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Deep Bio does
Deep Bio is a Seoul, South Korea-based medical AI company founded in 2015 that develops deep learning software for digital pathology, with a primary focus on cancer detection, grading, and quantification in prostate and breast tissue specimens. Its core product suite, branded DeepDx, analyzes H&E-stained and IHC-stained whole-slide images to detect cancer, assign Gleason scores, quantify tumor area, and (in newer modules) predict recurrence risk. The underlying technology includes the proprietary YAAGGS weakly-supervised learning model, which reduces dependence on region-level manual annotations and supports generalization across varying staining protocols. The portfolio includes DeepDx Prostate for core needle biopsy, radical prostatectomy, and TURP specimens; DeepDx Breast for resection and sentinel lymph node biopsy; and DeepCDx Membrane IHC for immunohistochemistry analysis.
The company's go-to-market operates through three channels: direct enterprise sales to Korean public hospitals via the Public Procurement Service (where DeepDx Prostate Pro holds Innovative Product designation), distribution partnerships with global digital pathology platform vendors (Roche navify, PathAI AISight, Visiopharm, Indica Labs HALO AP, Gestalt PathFlow, Tribun Health CaloPix, Lumea) for international reach, and research collaborations with academic medical centers including Stanford Medicine, ARUP Laboratories, Dana-Farber Cancer Institute, and Seoul National University Hospital. Revenue is generated via B2B licensing and subscription arrangements with hospitals, pathology labs, and platform integrators; pricing is not publicly disclosed and is negotiated on a quote basis. The company achieved MFDS Class III approval in November 2021 — the first AI cancer diagnostic support software to do so in Korea — and holds MDSAP, ISO 13485, ISO 27001, ISO 27701, and KGMP certifications, providing regulatory access to the US, Canada, Japan, Australia, and Brazil.
As of early 2026 the company was operating with a reduced team of approximately nine employees (down from roughly 30), pursuing a small bridge financing round, and relying on its platform-vendor distribution partners to penetrate the US hospital market. Product investment and partnership activity remain active, with the most recent launches including DeepCDx Membrane IHC (May 2025), a prognostic AI algorithm for prostate cancer (April 2025), and a breast cancer recurrence risk model (October 2025).
Deep Bio firmographics
Firmographics- Name
- Deep Bio
- Legal name
- 주식회사 딥바이오 (Deep Bio Inc.)
- Website
- https://deepbio.co.kr
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Deep Bio is a Seoul-based medical AI company developing deep learning software for digital pathology, primarily for prostate and breast cancer detection and grading on whole-slide images, sold to hospitals and pathology labs via licensing and integration with major digital pathology platforms including Roche and PathAI.
- Ownership category
- akta.pro rank
Deep Bio industry classification
Industry- Product category
- Digital Pathology AI Diagnostics
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
- akta.pro secondary industries
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Medical Imaging AI (HDAAAEAH), Anatomic Pathology LIS & Digital Pathology Workflow (HLACAMAB)
Keywords
Where Deep Bio is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices1 record
Markets served
Deep Bio business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- AI Diagnostic Software Licensing: B2B licensing of DeepDx Prostate AI diagnostic software to hospitals, pathology labs, and digital pathology platform providers. Software analyzed over 500k cores at US CLIA labs as of June 2021, indicating commercial usage and testing volume.
- Enterprise Software Sales: Direct enterprise sales to hospitals for clinical use, with active pipeline including U.S. hospital deals in contracting stage.
- Platform Integration Licensing: Licensing arrangements with digital pathology platform vendors (Roche navify, PathAI AISight, Visiopharm, Indica Labs HALO) for integration of AI algorithms into their platforms.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise licensing for hospitals and pathology labs |
Go-to-market motion3 records
Distribution channels9 records
Marketing channels5 records
Deep Bio product offering
Product offeringCore offering
Deep Bio develops and sells AI-powered digital pathology software (the DeepDx suite) that analyzes whole-slide images of H&E-stained and IHC-stained tissue specimens to detect, grade, and quantify cancer. The software targets prostate cancer (core needle biopsy, radical prostatectomy, TURP specimens) and breast cancer (resection, sentinel lymph node biopsy), and is licensed to hospitals, pathology labs, and integrated into major digital pathology platforms including Roche navify, PathAI AISight, Visiopharm, Indica Labs HALO AP, Gestalt PathFlow, and Tribun Health CaloPix.
Product overview
Deep Bio offers DeepDx, a unified suite of AI-powered cancer diagnostic solutions for digital pathology. The portfolio includes specialized products for prostate cancer analysis across three specimen types — DeepDx Prostate for core needle biopsy (CNB), radical prostatectomy (RP), and transurethral resection of the prostate (TURP) — and breast cancer analysis for resection specimens and sentinel lymph node biopsy (SLNB). All products analyze digitized whole-slide tissue images using proprietary deep learning algorithms to detect cancer, grade severity, and quantify tumor metrics. The suite is anchored by the DeepDx Viewer for image visualization. The products share a common AI technology platform, with models trained on H&E-stained and IHC-stained specimens, and are integrated into multiple third-party digital pathology platforms (PathAI AISight, Visiopharm, Indica Labs HALO AP, Gestalt PathFlow, Tribun Health CaloPix) for broad market access.
Differentiator
Problem solved
Functional benefit
Brands
- DeepDx: AI-powered diagnostic software suite for cancer detection and analysis
- DeepDx Prostate
- DeepDx Prostate Pro
- DeepCDx Membrane IHC
- DeepDx Breast
Products and services
- DeepDx Viewer A general-purpose digital pathology image viewer for viewing and interacting with digitized whole-slide tissue specimens. Serves as the visualization layer for the DeepDx AI suite.
- DeepDx Prostate – CNB (Core Needle Biopsy) AI-powered prostate cancer diagnostic support software for core needle biopsy specimens. Analyzes H&E-stained whole-slide images to automatically detect prostate cancer, assign Gleason scores and grade groups, and quantify tumor area. MFDS-approved Class III medical device.
- DeepDx Prostate – RP (Radical Prostatectomy) AI analysis solution for prostate cancer detection and grading on radical prostatectomy (RP) whole-mount specimens. Extends DeepDx Prostate capabilities from biopsy to surgical resection specimens.
- DeepDx Prostate – TURP AI software that detects prostate cancer in specimens collected via transurethral resection of the prostate (TURP), performed on patients with benign prostatic hyperplasia. Enables cancer detection beyond standard biopsies.
- DeepDx Breast – Resection AI-powered breast cancer diagnostic solution for resection tissue specimens. Differentiates breast cancer lesions accurately using deep learning algorithms for surgical resection samples.
- DeepDx Breast – SLNB (Sentinel Lymph Node Biopsy) AI solution for detecting breast cancer metastasis in sentinel lymph node biopsy (SLNB) specimens. Supports breast cancer staging by analyzing lymph node tissue for metastatic spread during surgical management.
Quantifiable outcome
- 99% sensitivity and 94% specificity in clinical validation study
- +4 more outcomes
Companies that use Deep Bio
Customer profileNamed customers9 records
Segments4 records
Ideal customer profiles3 records
Deep Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability4 records
Feature4 records
Deep Bio partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core, strategic and major.
- PathAIcorePathAI announced integration of Deep Bio's prostate cancer analysis solution (DeepDx Prostate) into its AISight Image Management System, combining AI tools for prostate, breast, and lung cancer diagnostics to improve pathology workflows.
- Roche DiagnosticscoreDeep Bio announced collaboration with Roche to integrate its advanced suite of AI algorithms into the navify Digital Pathology enterprise software, enabling broader market access through Roche's established hospital relationships.
- ABIONstrategicMOU signed to advance AI-driven companion diagnostics and clinical trials, leveraging cutting-edge AI technologies for biomarker discovery in life sciences sector.
- VisiopharmcoreCollaborative integration of clinical-grade AI prostate cancer grading solution with Visiopharm's leading digital pathology platform, providing pathologists access to state-of-the-art AI prostate cancer analysis.
- Indica LabscoreDeep Bio successfully integrated DeepDx Prostate algorithm into the HALO AP platform from Indica Labs, enabling high throughput diagnostic process for pathologists.
- Tribun HealthcoreCollaboration agreement with Paris-based Tribun Health to integrate DeepDx Prostate into their CaloPix platform for AI-powered digital pathology, strengthening presence in Europe and Canada.
- Dana-Farber Cancer InstitutestrategicRenewed research collaboration as part of MADCaP Consortium to evaluate DeepDx Prostate for prostate cancer tumor analysis across Sub-Saharan Africa centers, led by Dr. Timothy Rebbeck.
- Stanford MedicinestrategicExtended software license agreement for DeepDx Prostate to be used in Stanford research study on radical prostatectomy specimens, evaluating AI performance against researcher diagnosis data.
- ARUP LaboratoriesstrategicResearch collaboration to evaluate whether applying DeepDx Prostate in ARUP's pathology workflow can lead to higher diagnostic performance compared to microscope-based diagnosis.
- Gestalt DiagnosticsmajorStrategic relationship for development of integrated workflow allowing pathologists to use AI algorithms directly within Gestalt's PathFlow platform for prostate cancer diagnosis.
- LumeamajorCommercial partnership with US-based digital pathology solution company Lumea for distribution of DeepDx Prostate products and commercial rights for image use.
- Samsung Medical CenterstrategicCollaborative research partner for multiple studies including c-MET expression analysis and various cancer diagnostic research projects.
- Hanyang University Medical CenterstrategicProvided specimens (7,600 H&E-stained prostate core needle biopsy samples) for YAAGGS study training and validation.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
Deep Bio competitors and assessment
Company assessmentDirect peers
- AIRA Matrix: India-based AI pathology company offering deep-learning solutions for cancer detection in digital pathology; comparable in scope and customer type to Deep Bio's product suite.
- Paige.AI: Direct AI pathology competitor offering FDA-authorized AI cancer detection products for prostate and breast; competes for the same hospital and reference-lab customers with overlapping product surface.
- Ibex Medical Analytics: AI pathology vendor with clinically deployed prostate and breast cancer detection products; directly comparable to DeepDx Prostate in customer use cases and clinical settings.
- PathAI: Both partner and competitor: PathAI's AISight hosts Deep Bio's prostate AI but also develops its own cancer detection algorithms, making it the closest peer in technology stack and target customer.
- Owkin: AI pathology and biomarker discovery platform targeting pharma and clinical customers with deep-learning cancer diagnostics; overlaps with Deep Bio on AI pathology and emerging companion-diagnostic ambitions.
- Proscia: Digital pathology platform that competes with the same DeepDx-style AI workflow positioning; Proscia's Concentriq platform is an alternative integration channel to PathAI/Roche navify.
Regional players
- Lunit: Korean AI medical imaging company with Lunit INSIGHT for mammography and pathology-adjacent products; comparable as a Korean peer pursuing AI in oncology diagnostics with global commercial ambitions.
Broad incumbents
- Roche (navify Digital Pathology): Large incumbent enterprise pathology platform that both hosts Deep Bio's AI and competes for AI workflow dollars; comparable as the dominant platform-level player shaping go-to-market.
- Philips Digital Pathology: Large incumbent with IntelliSite digital pathology platform and AI partnerships; comparable as an established pathology vendor competing for the same hospital budgets.
Others
- Visiopharm: Digital pathology platform partner that distributes Deep Bio's prostate AI; relevant because platform-vendor economics determine Deep Bio's channel access in clinical workflows.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Deep Bio social profiles
Digital presenceDeep Bio compliance and trust
Trust signalCompliance6 records
Deep Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Deep Bio leadership team
Management profileNumber of profiles
Profiles5 records
Deep Bio funding detail
Funding detailFunding overview
Funding rounds3 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Deep Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Deep Bio
What does Deep Bio do?
Deep Bio develops and sells AI-powered digital pathology software (the DeepDx suite) that analyzes whole-slide images of H&E-stained and IHC-stained tissue specimens to detect, grade, and quantify cancer. The software targets prostate cancer (core needle biopsy, radical prostatectomy, TURP specimens) and breast cancer (resection, sentinel lymph node biopsy), and is licensed to hospitals, pathology labs, and integrated into major digital pathology platforms including Roche navify, PathAI AISight, Visiopharm, Indica Labs HALO AP, Gestalt PathFlow, and Tribun Health CaloPix.
Is Deep Bio a public or private company?
Deep Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Deep Bio founded?
Deep Bio was founded in 2015. It employs 11 to 50 people.
Where is Deep Bio based?
Deep Bio is headquartered in Seoul, South Korea, in the Asia region.
How does Deep Bio make money?
Three revenue lines are on record. AI Diagnostic Software Licensing is the primary driver. The others are enterprise Software Sales and platform Integration Licensing.
Who are Deep Bio's main competitors?
Direct peers on record are AIRA Matrix, Paige.AI, Ibex Medical Analytics, PathAI, Owkin and Proscia. Lunit is listed as a regional player. Broad incumbents are Roche (navify Digital Pathology) and Philips Digital Pathology. Visiopharm is listed as an others.
Does Deep Bio have an API?
No public API is recorded for Deep Bio.
What industry is Deep Bio in?
Deep Bio's product category is Digital Pathology AI Diagnostics. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its NAICS code is 621511 and its SIC code is 2835.